Monitoring immune function with molecular imaging could have a considerable impact on the diagnosis and treatment evaluation of immunological disorders and therapeutic immune responses. Positron emission tomography (PET) is a molecular imaging modality with applications in cancer and other diseases. PET studies of immune function have been limited by a lack of specialized probes. Imaging of the immune system in living subjects can define the spatiotemporal programming of innate and adaptive immunity. PET enables noninvasive, quantitative and tomographic assays of biological processes by using molecular probes labeled with positron-emitting radioisotopes 1 . Studies in mice have shown that PET is useful to visualize immune responses and antitumor T cell responses can be monitored by PET reporter gene imaging [2] [3] [4] [5] [6] . Using a mouse model of autoimmune demyelination, we showed that 18 fluorodeoxyglucose ([ 18 F]FDG) PET allows imaging of disease onset and of immunosuppressive therapy 7 . However, [ 18 F]FDG accumulation in tissues like heart, brain and liver suggests the need for new PET probes with other biodistribution patterns. To develop such probes, we focused on the salvage pathway for DNA synthesis in which deoxyribonucleosides are converted to nucleotides by phosphorylation catalyzed by deoxyribonucleoside kinases (reviewed in ref. 8). Although most tissues predominantly utilize the de novo pathway for DNA synthesis, lymphoid organs and rapidly proliferating tissues rely extensively on the salvage pathway 9 . To identify new probes for the salvage pathway, we (i) in vitro screened nucleoside analogs for differential retention in proliferating and quiescent T cells, (ii) identified FAC, a new PET probe candidate with increased accumulation in proliferating T cells, (iii) performed gene expression and biochemical analyses to investigate the mechanism(s) of elevated FAC retention, (iv) radiochemically synthesized 
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RESULTS

Differential screening to identify PET probes for T cell activation
We measured the retention of [ 3 H]-labeled deoxyribonucleoside analogs in resting versus proliferating primary CD8 + T cells. The selection criteria for deoxyribonucleoside analogs took into account the propensity of fluorine substitutions to change the biochemical properties of nucleosides (reviewed in ref. 10) . As fluorination at C4¢ is incompatible with 18 F-labeling, and fluorination at C5¢ would prevent phosphorylation by nucleoside kinases, we tested only deoxyribonucleoside analogs containing 'cold' fluorine ( 19 F) atom substitutions at C2¢ or C3¢ on the sugar moiety or at position 5 of the nucleobase ( Supplementary Fig. 1 online) . We found wide variation in deoxyribonucleoside analog retention by quiescent and proliferating CD8 + T cells (Fig. 1a) . Whereas 2¢,2¢-difluorodeoxycytidine (dFdC; Fig. 1b Supplementary  Fig. 2 online) . Relative to the stereochemical configurations of the C2¢ fluorine atom (Fig. 1b) , the F-ara ('up') analogs retain biological activity, whereas the C2¢ ribo ('down') compounds are inactive (reviewed in ref. 10). Indeed, similar amounts of the F-ara analog 1-(2-deoxy-2-fluoro-arabinofuranosyl)-cytosine (FAC; Fig. 1b ) and dFdC were retained in proliferating CD8 + T cells (Fig. 1c) Fig. 3a and Supplementary Movies 1-4 online). Imaging data were corroborated with radioactivity measurements in necropsy tissue samples ( Supplementary  Fig. 3c ) and with digital whole-body autoradiography (DWBA; Fig. 2a ). One hour after injection of [ 18 F]FAC, accumulated radioactivity was detected in thymus, spleen, intestine, bone and bone marrow and liver. Similar to other deoxycytidine analogs, FAC is susceptible to deamination in vivo 16 ( Supplementary Fig. 4 by T cell priming by strong xenoantigens encoded by the gag and env genes of the Moloney murine sarcoma and leukemia virus complex (MoMSV). As shown by conventional ex vivo approaches 20 and PET reporter gene imaging 3, 6 , nonmetastatic MoMSV-induced sarcomas are rejected in a T cell-dependent manner with reproducible kinetics. [ 18 F]FAC scans at the peak of the antitumor immune response (day 15) indicated increased accumulation in the spleen and tumor draining lymph nodes (DLNs) relative to day -1 baseline scans (Fig. 3a,b and Supplementary Fig. 6 Fig. 3d and Supplementary Fig. 6 ). (Fig. 3a,d and Supplementary  Fig. 6 to lymphadenopathy, arthritis and immune complex-mediated glomerulonephrosis 21 . We used B6.MRL-Fas lpr /J mice, which show slower disease progression than the MRL/Mp-lpr/lpr strain 22 . PET-CT scans of 2-3-month-old B6.MRL-Fas lpr /J mice revealed increased numbers of [ 18 F]FAC-positive axillary and brachial lymph nodes relative to age-matched wild-type (WT) C57BL/6J controls ( Fig. 4 and Supplementary Fig. 7a online) . showed an excellent correlation between retained radioactivity and T cell numbers ( Supplementary Fig. 7b ). To determine whether [ 18 F]FAC microPET-CT could monitor therapy, B6.MRL-Fas lpr /J mice were given dexamethasone, a synthetic glucocorticoid with potent immunosuppressive effects 23 . Dexamethasone had a profound effect on [ 18 F]FAC retention in thymus and lymph nodes, presumably reflecting the cytotoxic effects of this drug toward lymphocytes (Fig. 4 and Supplementary Fig. 7a ). Supplementary Fig. 8 online) . Increased prodrugs cytarabine (Ara-C) and 2¢-difluorodeoxycytidine (dFdC, gemcitabine). Similar to the mechanism of FAC retention, the activation of these widely used prodrugs requires uptake via nucleoside transporters and dCK-mediated phosphorylation (reviewed in ref. 
DISCUSSION
T cell activation and radioactive tracer uptake assay. We stimulated T lymphocytes from Pmel-1 T cell receptor-transgenic mice 24 Micro-positron emission tomography-computed tomography imaging. We kept mice warm under gas anesthesia (2% isoflurane), injected them intravenously with 200 mCi of various PET probes and allowed uptake for 1 h. We then positioned mice in an imaging chamber. We acquired data with the Siemens Preclinical Solutions microPET Focus 220 and MicroCAT II CT systems. We acquired microPET data for 10 min and reconstructed them with a statistical maximum a posteriori probability algorithm (MAP) 28 into multiple frames. The spatial resolution of PET is B1.5 mm with 0.4 mm voxel size. CT images are a low-dose 400 mm resolution acquisition with 200 mm voxel size. We co-registered microPET and CT images as previously described 29 . We performed quantification by drawing three-dimensional regions of interest with AMIDE software 30 . The color scale is proportional to tissue concentration, with red being the highest and yellow, green and blue corresponding to the lower values.
Animal models for immune activation. We bred and maintained the mice used in these studies according to the guidelines of the UCLA Animal Research Committee. The MoMSV sarcoma model has been described previously 3 . We purchased B6.MRL-Fas lpr /J mice used for systemic autoimmunity studies from The Jackson Laboratory (stock number: 000482). We administered dexamethasone (10 mg/kg) by intraperitoneal injection in 100 ml PBS at 24-h intervals for 2-7 d. Mice were scanned by microPET-CT 24 h after the last injection.
Digital whole-body autoradiography. Mice were injected intravenously with 1 mCi [ 18 F]FAC and killed 1 h later. We performed DWBA using previously described methods 7 . We exposed frozen coronal whole-body sections from mice (45 mm-thick) overnight and developed them with a Fuji BAS 5000 Imager at 100 mm spatial resolution.
Statistical analyses. We constructed graphs with GraphPad Prism software, version 4.02. We calculated P values with Student's t-test. P values of o0.05 were considered significant. Data are presented as means ± s.e.m.
Additional methods. Detailed methodology is described in Supplementary Methods online.
Note: Supplementary information is available on the Nature Medicine website.
